Erratum: “Links Between Subclinical Thyroid Dysfunction and Cardiovascular Risk Factors by Age and Gender”
-
February 11, 2025
February 11, 2025
by Sungho Bea, Hwa Young Ahn, Jieun Woo, Ju-Young Shin, Sun Wook Cho
December 9, 2024
Most surgeons reported using intraoperative parathyroid hormone monitoring, but approaches to imaging and intraoperative criteria varied, particularly in secondary and tertiary disease
April 13, 2026
Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.
June 16, 2026